Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Product Name |
| FCN-H52W7 | Human FcRn / FCGRT&B2M Heterodimer Protein, His Tag (SPR & BLI & MALS verified) |
| FCA-H52H1 | Human Fc gamma RI / CD64 Protein, His Tag (SPR & BLI & MALS verified) |
| CDA-H5221 | Human Fc gamma RIIA / CD32a (R167) Protein, His Tag (MALS & BLI verified) |
| CD1-H5223 | Human Fc gamma RIIA / CD32a (H167) Protein, His Tag (SPR & BLI & MALS verified) |
| CDB-H5228 | Human Fc gamma RIIB/C (CD32b/c) Protein, His Tag (SPR & BLI & MALS verified) |
| CD8-H52H4 | Human Fc gamma RIIIA / CD16a (V176) Protein, His Tag (SPR & BLI & MALS verified) |
| CDA-H5220 | Human Fc gamma RIIIA / CD16a (F176) Protein, His Tag (MALS & SPR verified) |
| CDB-H5227 | Human Fc gamma RIIIB / CD16b (NA1) Protein, His Tag (SPR & BLI & MALS verified) |
| CDB-H5222 | Human Fc gamma RIIIB / CD16b (NA2) Protein, His Tag (SPR & BLI & MALS verified) |
Comprehensive FcRs Protein Panel – No separate purchasing needed
High Purity – >95% by SDS-PAGE; >90% by SEC-MALS
Robust Stability – High batch-to-batch consistency
Full Data Package – SPR, BLI, and ELISA activity data included
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
This product is stable after storage at:
Captured Human FCGRT&B2M Heterodimer Protein, His Tag (Cat. No. FCN-H52W7) on CM5 Chip via Anti-His antibody can bind Herceptin® (Trastuzumab) with an affinity constant of 0.516 μM as determined in a SPR assay (Biacore T200) (QC tested).
Human CD64, His Tag (Cat. No. FCA-H52H1) captured on CM5 chip via anti-His antibody can bind Herceptin® with an affinity constant of 4.92 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Immobilized Human CD32a (R167), His Tag (Cat. No. CDA-H5221) on CM5 Chip via anti-His antibody, can bind Rituximab with an affinity constant of 3.12 μM as determined in a SPR assay (Biacore T200) (QC tested).
Immobilized Human CD32a (H167), His Tag (SPR & BLI verified) (Cat. No. CD1-H5223) on CM5 Chip via anti-His antibody, can bind Rituximab with an affinity constant of 1.45 μM as determined in a SPR assay (Biacore T200) (QC tested).
Immobilized Human CD32b/c, His Tag (Cat. No. CDB-H5228) on CM5 Chip via anti-His antibody, can bind Rituximab with an affinity constant of 15.1 μM as determined in a SPR assay (Biacore T200) (QC tested).
Immobilized Human CD16a (V176), His Tag (Cat. No. CD8-H52H4) on CM5 Chip via anti-His antibody, can bind Herceptin with an affinity constant of 0.463 μM as determined in SPR assay (Biacore T200) (QC tested).
Human CD16a (F176), His Tag (Cat. No. CDA-H5220) captured on CM5 chip via anti-His antibody can bind Rituximab biosimilar (Cat. No. CD0-M36) with an affinity constant of 1.18 µM as determined in a SPR assay (Biacore 8K) (QC tested).
Immobilized Human CD16b (NA1), His Tag (Cat. No. CDB-H5227) on CM5 Chip via anti-His antibody, can bind Rituximab with an affinity constant of 8.17 μM as determined in a SPR assay (Biacore T200) (QC tested).
Immobilized Human CD16b (NA2), His Tag (Cat. No. CDB-H5222) on CM5 Chip via anti-His antibody, can bind Rituximab with an affinity constant of 2.88 μM as determined in a SPR assay (Biacore T200) (QC tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
This web search service is supported by Google Inc.
A-Z
